Biomarkers such as neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) are particularly valuable for tracking neurodegeneration and glial activation, which are central to ALS pathology [18]. Here, NEFL is linked to amyotrophic lateral sclerosis.